Why the study?
Does renal ischemia-reperfusion induce release of angiopoietins and endothelial cell activation in human kidney transplantation?
Does renal ischemia-reperfusion induce release of angiopoietins and endothelial cell activation in human kidney transplantation?
Renal ischemia-reperfusion injury in human kidney transplantation induces acute endothelial cell activation and Ang-2 release, suggesting angiopoietin signaling as a potential therapeutic target to maintain vascular integrity.
Renal ischemia-reperfusion is associated with Ang-2 release and endothelial activation in kidney transplantation; hypothesis-generating for angiopoietin-targeted therapies.
BACKGROUND: Recent insights suggest that endothelial cell (EC) activation plays a major role in renal ischemia-reperfusion (I/R) injury. Interactions between ECs and pericytes via signaling molecules, including angiopoietins, are involved in maintenance of the vascular integrity. Experimental data have shown that enhancement of Angiopoietin (Ang)-1 signaling might be beneficial in renal I/R injury. However, little is known about the role of angiopoietins in human renal I/R injury. METHODS: In this study, EC activation and changes in angiopoeitins are assessed in human living-donor (LD) and deceased-donor (DD) kidney transplantation. Local release of angiopoietins was measured by unique, dynamic arteriovenous measurements over the reperfused kidney. RESULTS: Renal I/R is associated with acute EC activation shown by a vast Ang-2 release from both LD and DD shortly after reperfusion. Its counterpart Ang-1 was not released. Histologic analysis of kidney biopsies showed EC loss after reperfusion. Baseline protein and mRNA Ang-1 expression was significantly reduced in DD compared with LD and declined further after reperfusion. CONCLUSIONS: Human renal I/R injury induces EC activation after reperfusion reflected by Ang-2 release from the kidney. Interventions aimed at maintenance of vascular integrity by modulating angiopoietin signaling may be promising in human clinical kidney transplantation.
No takes yet. Share an insight, caveat, or question.
Vries et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: